Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. It is grouped under the following drug class(es): Kinase inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Irbinitinib, Tukysa and tucatinibum. Its PubChem CID is 51039094.
Tucatinib
| CAS No | 937263-43-9 |
|---|---|
| Molecular Formula | C26H24N8O2 |
| Molecular Weight | 480.5 g/mol |
| Synonyms | 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.
The listed CAS number is 937263-43-9.
The listed molecular formula is C26H24N8O2.
The listed molecular weight is 480.5 g/mol.
6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine.
The source lists Irbinitinib, Tukysa and tucatinibum.